{{Rsnum
|rsid=2303428
|Gene=MSH2
|Chromosome=2
|position=47476361
|Orientation=plus
|GMAF=0.1286
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=MSH2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 19.5 | 80.5
| HCB | 10.2 | 40.1 | 49.6
| JPT | 13.3 | 45.1 | 41.6
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 7.0 | 93.0
| CHB | 10.2 | 40.1 | 49.6
| CHD | 9.2 | 50.5 | 40.4
| GIH | 1.0 | 16.8 | 82.2
| LWK | 0.0 | 2.7 | 97.3
| MEX | 0.0 | 12.1 | 87.9
| MKK | 0.0 | 7.1 | 92.9
| TSI | 2.0 | 12.7 | 85.3
| HapMapRevision=28
}}{{PMID Auto
|PMID=19741564
|Title=Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians
}}

{{ClinVar
|rsid=2303428
|Reversed=0
|FwdREF=T
|FwdALT=A,C,G
|REF=T
|ALT=A,C,G
|RSPOS=47703500
|CHROM=2
|GMAF=0.1282
|dbSNPBuildID=100
|SSR=0
|SAO=1
|VP=0x050168000000150517100104
|GENEINFO=MSH2:4436
|GENE_NAME=MSH2
|GENE_ID=4436
|WGT=0
|VC=SNV
|CLNALLE=2; 3
|CLNHGVS=NC_000002.11:g.47703500T>C; NC_000002.11:g.47703500T>G
|CLNSRC=InSiGHT
|CLNORIGIN=1
|CLNSIG=2
|CLNDBN=Lynch syndrome; AllHighlyPenetrant
|Disease=Lynch syndrome; AllHighlyPenetrant
|Tags=PM;PMC;SLO;VLD;G5;HD;GNO;KGPhase1;KGPROD;OTHERKG;PH3;LSD;NOV
|CAF=0.8714; 0.1286; .
|CLNACC=RCV000030247.2; RCV000035359.2; RCV000076352.1
|CLNDSDB=GeneReviews:MedGen:SNOMED_CT; MedGen
|CLNDSDBID=NBK1211:C0009405:315058005; CN169374
|COMMON=1
|CLNSRCID=c.2006-6T>C; c.2006-6T>G
}}

{{PMID|16985024}} Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2.

{{PMID|19930554|OA=1
}} Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

{{PMID|20386703|OA=1
}} Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.

{{PMID|10978353|OA=1
}} Recurrent germline mutation in MSH2 arises frequently de novo.

{{PMID|17374836}} MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer.

{{PMID|18325052}} Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}